<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Travoprost: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Travoprost: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Travoprost: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11114" href="/d/html/11114.html" rel="external">see "Travoprost: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="97564" href="/d/html/97564.html" rel="external">see "Travoprost: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F230214"><span class="drugH1">Brand Names: US</span>
<ul>
<li>iDose TR;</li>
<li>Travatan Z</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868478"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Travoprost Z [DSC];</li>
<li>Izba;</li>
<li>SANDOZ Travoprost;</li>
<li>TEVA-Travoprost Z [DSC];</li>
<li>Travatan Z</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F230234"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ophthalmic Agent, Antiglaucoma;</li>
<li>
                        Prostaglandin, Ophthalmic</li></ul></div>
<div class="block doa drugH1Div" id="F230217"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a6687a47-d77d-4bbc-a712-b27b54e1af1f">Ocular hypertension/glaucoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular hypertension/glaucoma (open-angle):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ocular implant: <b>Intracameral:</b> Insert 1 implant into affected eye(s); do not readminister.</p>
<p style="text-indent:-2em;margin-left:4em;">Ocular solution: <b>Ophthalmic:</b> Instill 1 drop into affected eye(s) once daily in the evening; do not exceed once-daily dosing (may decrease intraocular pressure-lowering effect).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990274"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; dosage adjustments are unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50987493"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; dosage adjustments are unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F230218"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F20202793"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="97564" href="/d/html/97564.html" rel="external">see "Travoprost: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60f91e7f-5b7f-4b65-8d79-2634ab361d31">Elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure (IOP): </b>Ophthalmic: Infants ≥2 months, Children, and Adolescents: Limited data available: 1 drop into affected eye(s) once daily in the evening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28887006','lexi-content-ref-19233013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28887006','lexi-content-ref-19233013'])">Ref</a></span>). <b>Note:</b> Do not exceed once-daily dosing (may decrease IOP-lowering effect).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51192981"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments are unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51192982"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments are unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F230190"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Ocular hyperemia (30% to 50%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (1% to 5%), bradycardia (1% to 5%), chest pain (1% to 5%), hypertension (1% to 5%), hypotension (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Foreign body sensation of eye (5% to 10%), anxiety (1% to 5%), depression (1% to 5%), headache (1% to 5%), pain (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperpigmentation of eyelashes, increased growth in number of eyelashes</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (1% to 5%), gastrointestinal distress (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Prostatic disease (1% to 5%), urinary incontinence (1% to 5%), urinary tract infection (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (1% to 5%), back pain (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased visual acuity (5% to 10%), eye discomfort (5% to 10%), eye pain (5% to 10%), eye pruritus (5% to 10%), blepharitis (1% to 4%), blurred vision (1% to 4%), cataract (1% to 4%), conjunctivitis (1% to 4%), corneal staining (1% to 4%), crusting of eyelid (1% to 4%), dry eye syndrome (1% to 4%), hyperpigmentation of eyelids (periorbital; 1% to 4%), iris discoloration (1% to 4%), keratitis (1% to 4%), lacrimation (1% to 4%), ophthalmic inflammation (1% to 4%), photophobia (1% to 4%), subconjunctival hemorrhage (1% to 4%), visual disturbance (1% to 4%), increased eyelash length, increased eyelash thickness</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1% to 5%), flu-like symptoms (1% to 5%), sinusitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, arthralgia, asthma, bacterial keratitis (due to solution contamination), cardiac arrhythmia, chest discomfort, corneal edema, cystoid macular edema, diarrhea, dyspnea, dysuria, enophthalmos, epistaxis, erythema of skin, insomnia, iritis, macular edema, musculoskeletal pain, nausea, prostate specific antigen increase, pruritus, tachycardia, tinnitus, uveitis, vomiting</p></div>
<div class="block coi drugH1Div" id="F230202"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular implant:</b> Hypersensitivity to travoprost or any component of the formulation; active or suspected ocular or periocular infection; corneal endothelial cell dystrophy (eg, Fuch dystrophy, corneal guttata); prior corneal transplantation or endothelial cell transplants (eg, Descemet stripping automated endothelial keratoplasty).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular solution:</b> There are no contraindications listed in the US manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to travoprost or any component of the formulation; pregnancy or women attempting to become pregnant.</p></div>
<div class="block war drugH1Div" id="F230188"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bacterial keratitis: Ocular solution: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Eye color changes: May change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes; length and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the periorbital tissue and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular inflammation: Intraocular inflammation and exacerbation of inflammation may occur; use with caution in patients with a history of intraocular inflammation (eg, iritis/uveitis) and generally avoid use in patients with active intraocular inflammation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aphakia or pseudoaphakia: Topical prostaglandin analogues have been associated with the occurrence/exacerbation of macular edema, including cystoid macular edema. Carefully examine the macula in these patients especially those with an open posterior capsule.</p>
<p style="text-indent:-2em;margin-left:4em;">• Herpetic keratitis: Use with caution in patients with a history of herpes simplex keratitis; reactivation may occur. Avoid use in patients with active herpes simplex keratitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Iridocorneal angles: Ocular implant: Use with caution in patients with narrow iridocorneal angles (Shaffer grade &lt;3) or other angle abnormalities (eg, peripheral anterior synechia, rubeosis iridis); may impair proper placement of implant.</p>
<p style="text-indent:-2em;margin-left:4em;">• Uveitis: Use cautiously in patients with intraocular inflammation as topical prostaglandins may worsen inflammation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Ocular solution: Remove contact lens prior to instillation; may reinsert 15 minutes following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use ocular solution in pediatric patients (&lt;16 years of age) is not recommended by the manufacturer due to possible safety issues of increased pigmentation following long-term chronic use. Safety and efficacy of ocular implant has not been established in pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular implant: Dislocation has occurred; surgically remove if implant becomes dislocated. Endophthalmitis has occurred with intraocular surgical procedures and injections; ensure proper aseptic technique is used during administration. Implant is MRI conditional; patients should inform health care providers of implant prior to MRI.</p></div>
<div class="block foc drugH1Div" id="F230196"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Implant, Intraocular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">iDose TR: 75 mcg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Travatan Z: 0.004% (2.5 mL, 5 mL) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Travatan Z: 0.004% (2.5 mL [DSC], 5 mL [DSC]) [benzalkonium free; contains polyoxyl/peg-35 castor oil(cremophor el), propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.004% (2.5 mL, 5 mL)</p></div>
<div class="block geq drugH1Div" id="F230184"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F230204"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Implant</b> (iDose TR Intraocular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mcg (per each): $16,740.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Travatan Z Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.004% (per mL): $107.44</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Travoprost (BAK Free) Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.004% (per mL): $79.34 - $83.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868479"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Izba: 0.003% (2.5 mL, 5 mL) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Travatan Z: 0.004% (2.5 mL, 5 mL) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.004% (2.5 mL, 5 mL)</p></div>
<div class="block adm drugH1Div" id="F230199"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Ocular implant:</i> Anesthetize eye using general, retrobulbar, peribulbar, or topical anesthesia prior to inserting; may administer an intracameral miotic to deepen the angle prior to implant insertion. Administer from the temporal side, using a temporal clear corneal incision; implant intracamerally through the angle and the trabecular meshwork into the sclera on the nasal side. Once implanted, apply slight pressure to the sides of the implant with the tip of the inserter to ensure the implant is fully anchored into scleral tissue. If the initial implant is loose or disengaged, remove and reimplant a minimum of ½ clock hour to either side of initial implant try; do not reimplant at the same location. Perform a high magnification examination to confirm the implant is in proper position. Refer to manufacturer's prescribing information for additional administration instructions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Ocular solution:</i> May be used with other eye drops to lower intraocular pressure. If using more than one ophthalmic product, wait at least 5 minutes in between application of each medication. Remove contact lenses prior to administration and wait 15 minutes (after administration) before reinserting. Minimize contamination by not touching the eyelids or surrounding areas with the dropper tip; keep bottle tightly closed when not in use. Use eyelid closure or nasolacrimal occlusion when applying topical medications to reduce systemic absorption.</p></div>
<div class="block admp drugH1Div" id="F52613960"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For ophthalmic use only. Travoprost may be used with other eye drops to lower intraocular pressure. If using more than one ophthalmic product, wait at least 5 minutes in between application of each medication. Apply gentle pressure to lacrimal sac immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>). Remove contact lenses prior to administration and wait 15 minutes (after administration) before reinserting. Avoid contact of bottle tip with skin or eye; ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions</p></div>
<div class="block use drugH1Div" id="F230197"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Ocular hypertension/glaucoma (open-angle):</b> Reduction of elevated intraocular pressure in adults (ocular implant, ocular solution) and pediatric patients ≥16 years of age (ocular solution) with open-angle glaucoma or ocular hypertension.</p></div>
<div class="block mst drugH1Div" id="F230240"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Travatan may be confused with Xalatan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300163"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223400"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Latanoprost: The concomitant use of Prostaglandins (Ophthalmic) and Latanoprost may result in increased intraocular pressure. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54386516"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Ophthalmic prostaglandins, such as travoprost, have a theoretical risk of miscarriage. To decrease this risk, agents other than travoprost may be preferred for the treatment of glaucoma in patients planning to become pregnant (Strelow 2020).</p></div>
<div class="block pri drugH1Div" id="F230205"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Ophthalmic prostaglandins, such as travoprost, are generally avoided during pregnancy due to a theoretical risk of miscarriage and premature labor. Agents other than travoprost may be preferred for the treatment of glaucoma during pregnancy, especially during the first trimester. In general, if ophthalmic agents are needed in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Belkin 2020; Prum 2016; Strelow 2020).</p></div>
<div class="block brc drugH1Div" id="F17918131"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if travoprost is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Due to their short half-lives, ophthalmic prostaglandins such as travoprost are considered compatible with breastfeeding; administering after breastfeeding may help decrease potential exposure to the infant via breast milk (Belkin 2020; Prum 2016; Strelow 2020).</p></div>
<div class="block mop drugH1Div" id="F53998610"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Ophthalmic exams (optic nerve and visual field assessment), serial measurement of intraocular pressure (IOP). Frequency of follow up based upon whether target IOP achieved, if there is any progression of damage, and how long disease has been controlled (AAO 2019); routinely confirm the location of the ocular implant.</p></div>
<div class="block pha drugH1Div" id="F230187"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A selective FP prostanoid receptor agonist which lowers intraocular pressure by increasing trabecular meshwork and outflow</p></div>
<div class="block phk drugH1Div" id="F230201"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Ocular solution: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Ocular solution: 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Absorbed via cornea; plasma levels &lt;10 pg/mL within 1 hour (ocular solution), 10 days (ocular implant).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hydrolyzed by esterases in the cornea to active free acid; systemically; the free acid is metabolized to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Ocular solution: 45 minutes (range: 17 to 86 minutes).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;2% as metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51204330"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: The intraocular pressure (IOP)-lowering effect of travoprost was shown to be 7 to 8 mm Hg among patients with a baseline pressure of 25 to 27 mm Hg in clinical studies. The mean IOP reduction was up to 1.8 mm Hg greater in Black patients, although it is not known if this increase can be attributed to race or to heavily pigmented irides.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F230206"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Glaucoprost | Glaunot | Glaunot sc | Neoprost | Travatan | Travoplos</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travo vision | Travoprost stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Avost | Trapost | Travagen z | Travast | Travatan | Travolar</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Vizitrav</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Travatan | Vizitrav</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Aitravic | Travamed | Travatan | Travatan bak free | Travoprosta | Travoptic</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travo vision | Travoprost mepha</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Avoplos | Glaucoprost | Tenoprox | Travatan | Travof sp</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Focus | Glaucoprost | Travatan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Travatan | Travoprost olikla | Travoprost polpharma | Travoprost stada</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travo vision | Travoprost 1 a pharma | Travoprost al | Travoprost heumann | Travoprost hexal | Travoprost omnivision | Travoprost ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acrotrav | Travatan | Travof sp | Xetiva</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travatan bak free | Travof sp | Travost</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Travatan | Travoprost elvim | Travoprost teva | Travoprost zentiva | Vizitrav</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travonorm</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Sinetrav | Travatan | Travoprost abamed | Travoprost stada | Travoprost vir | Visutrax | Vizitrav</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Izba | Travatan | Travoprost stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sinetrav | Travatan | Travoprost arrow | Travoprost bgr | Travoprost cristers | Travoprost eg | Travoprost mylan | Travoprost Sandoz | Travoprost teva | Travoprost zentiva | Vizitrav</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Izba | Travatan | Travoprost Sandoz | Visutrax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Trav iop | Travatan | Travoprost/rafarm | Vizitrav</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Protravis | Travatan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Izba | Travatan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aroprost z | Awarene pf | Klarprost | Lupitros | Lupitros z | Opacia | T 1 | Tavaren | Tovaxo | Travatan | Travisight | Travo | Travoflo | Travopta | Travopure | Travosoft | Travotas | Travstar pf | Trv | Xovatra | Zytrav</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acamba | Brunitrav | Izba | Menezon | Travatan | Traviop | Travoprost doc Generici | Travoprost eg | Travoprost mylan | Travoprost ntc | Travoprost Sandoz | Travoprost teva italia | Travoprost zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Travatanz | Travoprost nitto</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Taprost | Travatan | Travon eye</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Izba | Travatan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Travatan | Travoprost elvim | Travoprost polpharma | Travoprost Sandoz | Vizitrav</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travoprost eg | Vizitrav</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Travatan | Travoprost elvim</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bristrio | Conviss | FHintral | Loprogal | Luxagot pf | Osticro | Sorpova rt | Travatan | Tvt | Valdax | Zafestrol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Izba | Travatan | Travo</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Vitaprost</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travoprost CF | Travoprost Sandoz | Travoprost teva | Vizitrav</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Izba | Travatan | Travatan z</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travopt</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Glaunot | Levotuz | Travatan | Travof sp | Unitrav</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Eyprost | Ocutrav | Ocutrav z | Prostek | Travatan | Travop | Travost | Travson</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Lytrescio | Rozatrav | Travatan | Travoprost genoptim | Vizitrav</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travoprost ciclum | Visotan | Vizitrav</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Glaucoprost | Glaunot | Glausolet | Travatan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Izba | Travatan | Travocom | Travoprost zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Travapress | Travatan | Travaxal | Travoprost optic</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Izba | Travatan | Travoprost medical valley | Travoprost Sandoz | Travoprost stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Travatan | Travatan c</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bondulc | Travatan | Travoprost olikla | Travoprost polpharma</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Izba | Travatan | Travatan bak free</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Drasoter | Travatan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Izba | Travatan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Glautan | Travapress | Travatan | Travinor | Travonext</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Etacril | Glaucoprost | Travatan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Glaucoprost | Travatan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Travatan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAO.1">
<a name="AAO.1"></a>American Academy of Ophthalmology (AAO) PPP Glaucoma Panel, Hoskins Center for Quality Eye Care. Glaucoma summary benchmarks-2019, October 2019. Available online: https://www.aao.org/summary-benchmark-detail/glaucoma-summary-benchmarks-2019#PrimaryOpen-AngleGlaucoma(InitialEvaluation). Last accessed December 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Belkin.1">
<a name="Belkin.1"></a>Belkin A, Chen T, DeOliveria AR, et al. A practical guide to the pregnant and breastfeeding patient with glaucoma. <i>Ophthalmol</i>
<i>Glaucoma.</i> 2020;3:79-89.</div>
</li>
<li>
<div class="reference">
                  Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). US Food and Drug Administration website.<a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204822Orig1s000ClinPharmR.pdf" target="_blank"> https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204822Orig1s000ClinPharmR.pdf</a>. Published August 21, 2013. Accessed December 23, 2019.</div>
</li>
<li>
<div class="reference">
                  Center for Drug Evaluation and Research. Pharmacology review. US Food and Drug Administration website.<a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21257_Travatan_pharmr_P1.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21257_Travatan_pharmr_P1.pdf</a>. Published August 21, 2013. Accessed December 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28887006">
<a name="28887006"></a>Dixon ER, Landry T, Venkataraman S, et al. A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. <i>J AAPOS</i>. 2017;21(5):370-374.e1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/travoprost-drug-information/abstract-text/28887006/pubmed" id="28887006" target="_blank">28887006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-EMA.1">
<a name="EMA.1"></a>European Medicines Academy. Summary of product characteristics - travatan. https://www.ema.europa.eu/en/documents/product-information/travatan-epar-product-information_en.pdf Accessed December 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gupta.1">
<a name="Gupta.1"></a>Gupta N, Aung T, Congdon, Dada R, et al. International Council of Ophthalmology guidelines for glaucoma eye care. 2017. Available online: http://www.icoph.org/downloads/ICOGlaucomaGuidelines.pdf. Last accessed December 13, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-idosetr.1">
<a name="idosetr.1"></a>iDose TR (travoprost) [prescribing information]. San Clemente, CA: Glaukos Corp; December 2023.</div>
</li>
<li>
<div class="reference">
                  Izba (travoprost) [prescribing information]. Fort Worth, TX: Alcon Laboratories Inc; June 2021.</div>
</li>
<li>
<div class="reference">
                  Izba (travoprost) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26581556">
<a name="26581556"></a>Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern(®) guidelines. <i>Ophthalmology</i>. 2016;123(1):P41-P111. doi:10.1016/j.ophtha.2015.10.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/travoprost-drug-information/abstract-text/26581556/pubmed" id="26581556" target="_blank">26581556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31922978">
<a name="31922978"></a>Strelow B, Fleischman D. Glaucoma in pregnancy: an update. <i>Curr Opin Ophthalmol</i>. 2020;31(2):114-122. doi:10.1097/ICU.0000000000000641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/travoprost-drug-information/abstract-text/31922978/pubmed" id="31922978" target="_blank">31922978</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Travatan Z (travoprost) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</div>
</li>
<li>
<div class="reference">
                  Travatan Z (travoprost) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; February 2019.</div>
</li>
<li>
<div class="reference">
                  Travoprost ophthalmic solution [prescribing information]. Princeton, NJ: Sandoz Inc; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/travoprost-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19233013">
<a name="19233013"></a>Yanovitch TL, Enyedi LB, Schotthoeffer EO, Freedman SF. Travoprost in children: adverse effects and intraocular pressure response. <i>J AAPOS</i>. 2009;13(1):91-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/travoprost-drug-information/abstract-text/19233013/pubmed" id="19233013" target="_blank">19233013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984; 102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/travoprost-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10055 Version 217.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
